DermTech

OverviewSuggest Edit

DermTech is a diagnostics company developing and marketing non-invasive gene expression tests. It aims to provide aid in the diagnosis of various skin conditions, including skin cancer, inflammatory diseases, and aging-related conditions. The company provides an alternative to surgical biopsy and analyzes skin biopsy samples collected non-invasively using an adhesive patch.
TypePrivate
Founded1996
HQSan Diego, CA, US
Websitedermtech.com

Latest Updates

Employees (est.) (Dec 2019)60
Share Price (Jan 2021)$40.5 (+4%)
Cybersecurity ratingAMore

Key People/Management at DermTech

Gary Jacobs

Gary Jacobs

Director
Kevin Sun

Kevin Sun

Chief Financial Officer
Todd Wood

Todd Wood

Chief Commercial Officer
Zuxu Yao

Zuxu Yao

Chief Technical Officer
Claudia Ibarra

Claudia Ibarra

Chief Operating Officer
Burkhard Jansen

Burkhard Jansen

Chief Medical Officer
Show more

DermTech Office Locations

DermTech has an office in San Diego
San Diego, CA, US (HQ)
9404 Genesee Ave # 100, La Jolla
Show all (1)

DermTech Financials and Metrics

Summary Metrics

Founding Date

1996

DermTech total Funding

$5.6 m

DermTech latest funding size

$5.60 m

Time since last funding

7 years ago
DermTech's latest funding round in August 2013 was reported to be $5.6 m. In total, DermTech has raised $5.6 m
Show all financial metrics

DermTech Revenue

USD

Revenue (Q2, 2020)

844.0k

Gross profit (Q2, 2020)

(601.0k)

Gross profit margin (Q2, 2020), %

(71.2%)

Net income (Q2, 2020)

(9.4m)

EBIT (Q2, 2020)

(9.4m)

Cash (30-Jun-2020)

61.1m
Annual
USDFY, 2018FY, 2019

EBIT

(306.2k)(2.0m)

Interest income

1.2m

Investment income

2.9m

Net Income

856.4k944.5k
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q3, 2019Q1, 2020Q2, 2020

Revenue

565.0k1.6m844.0k

Cost of goods sold

779.0k1.2m1.4m

Gross profit

(214.0k)354.0k(601.0k)

Gross profit Margin, %

(38%)23%(71%)
Annual
USDFY, 2018FY, 2019

Cash

449.9k30.5k

Prepaid Expenses

93.5k51.3k

Current Assets

543.4k81.7k

Total Assets

146.9m12.4m
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q3, 2019Q1, 2020Q2, 2020

Cash

744.8k607.1k554.3k385.6k233.9k45.0k15.3k21.4m67.9m61.1m

Accounts Receivable

814.0k1.2m722.0k

Prepaid Expenses

98.6k97.7k67.1k67.5k77.5k41.2k45.8k1.4m892.0k547.0k

Inventories

44.0k75.0k83.0k
Annual
USDFY, 2018FY, 2019

Net Income

856.4k944.5k

Accounts Payable

26.4k1.5m

Cash From Operating Activities

(373.4k)(444.5k)

Cash From Investing Activities

(145.2m)136.9m
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q3, 2019Q1, 2020Q2, 2020

Net Income

(31.7k)214.7k466.4k443.8k445.8k949.4k(138.8k)(14.6m)(7.0m)(16.4m)

Depreciation and Amortization

58.0k60.0k148.0k

Inventories

(4.0k)(40.0k)(48.0k)

Accounts Payable

8.6k22.5k67.8k600.8k681.8k900.4k
USDQ1, 2018

Financial Leverage

29.2 x
Show all financial metrics

DermTech Cybersecurity Score

Cybersecurity ratingPremium dataset

A

91/100

SecurityScorecard logo

DermTech Online and Social Media Presence

Embed Graph

DermTech Blogs

DermTech Chief Scientific Officer Michael Howell Presented at Dermatology Summit 2021

DermTech Chief Scientific Officer Michael Howell Presented at Dermatology Summit 2021 Content Import Tue, 01/19/2021 - 16:31 DermTech Chief Scientific Officer Michael Howell Presented at Dermatology Summit 2021 January 19, 2021 at 4:30 PM EST This release is a…

DermTech Pigmented Lesion Assay (PLA) to Enrich Melanoma Positivity Nearly Five-Fold in Biopsied Lesions: Findings from a Large US Registry

LA JOLLA, Calif. --(BUSINESS WIRE)--Jan. 14, 2021-- DermTech , Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that SKIN has published the results of a large registry study finding that the evaluation of genomic

WKYC: Lydia Parker, M.D. – A New Way to Test for Skin Cancer

Alexa Lee from WKYC talks with dermatologist Dr. Lydia Parker about The Parker Skin & Aesthetic Clinic as well as a new, easy, way to test for skin cancer. The post WKYC: Lydia Parker, M.D. – A New Way to Test for Skin Cancer appeared first on DermTech.

DermTech Announces Inclusion of Non-Invasive Genomic Patch Testing in the National Comprehensive Cancer Network® (NCCN) Cutaneous Melanoma Guidelines

DermTech Announces Inclusion of Non-Invasive Genomic Patch Testing in the National Comprehensive Cancer Network® (NCCN) Cutaneous Melanoma Guidelines Content Import Tue, 01/12/2021 - 16:02 DermTech Announces Inclusion of Non-Invasive Genomic Patch Testing in the National Comprehensive Canc…

DermTech Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

LA JOLLA, Calif. --(BUSINESS WIRE)--Jan. 11, 2021-- DermTech, Inc. (Nasdaq: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the closing of its previously announced underwritten public offering of 4,872,881 shares of its common

DermTech Announces Pricing of Public Offering of Common Stock

DermTech Announces Pricing of Public Offering of Common Stock Content Import Thu, 01/07/2021 - 00:01 DermTech Announces Pricing of Public Offering of Common Stock January 7, 2021 at 12:00 AM EST This release is a backfill from a News Wire Genera…
Show more

DermTech Frequently Asked Questions

  • When was DermTech founded?

    DermTech was founded in 1996.

  • Who are DermTech key executives?

    DermTech's key executives are Gary Jacobs, Kevin Sun and Todd Wood.

  • How many employees does DermTech have?

    DermTech has 60 employees.

  • Who are DermTech competitors?

    Competitors of DermTech include CirculoGene, CGC Genetics and Complement Genomics.

  • Where is DermTech headquarters?

    DermTech headquarters is located at 9404 Genesee Ave # 100, La Jolla, San Diego.

  • Where are DermTech offices?

    DermTech has an office in San Diego.

  • How many offices does DermTech have?

    DermTech has 1 office.